Lung Cancer Screening Software Market: Market Size & Forecast 2026

Lung cancer screening software comprises a range of clinical and administrative tools that support the detection, tracking, and management of pulmonary nodules identified through low-dose computed tomography (LDCT) scans. The market was valued at $3.84 billion in 2025 and is on a growth trajectory toward approximately $8.67 billion by 2034, supported by a 6.9% annual compound growth rate. This expansion reflects a broader trend across the lung cancer diagnostics sector, where overall market activity is also growing rapidly as healthcare providers adopt more systematic screening protocols.

• •Market valued at $3.84 billion in 2025, with a projected CAGR of 6.9% through 2034
• •Supports LDCT-based screening programs for high-risk patient populations
• •Adjacent lung cancer diagnostics market reached $5.35 billion in 2025 and is expected to grow to $9.45 billion by 2034

Increasing global incidence of lung cancer, particularly linked to smoking prevalence and environmental factors, remains a primary catalyst for market expansion. Wider adoption of evidence-based screening guidelines by healthcare authorities and payers is bringing more eligible patients into screening programs, directly increasing demand for software infrastructure. Meanwhile, the integration of artificial intelligence and machine learning into imaging workflows is improving the speed and accuracy of nodule detection, making screening programs more clinically and economically viable.

• •Rising lung cancer incidence and aging demographics expanding the addressable screening population
• •Expanding screening guidelines and insurance coverage driving broader patient enrollment
• •AI-powered image analysis and cloud-based platforms reducing radiologist burden and improving diagnostic accuracy

The market is typically segmented by product type, including cloud-based and on-premises solutions, as well as by end-user category spanning hospitals, diagnostic imaging centers, and research institutions. North America currently leads the market due to strong healthcare infrastructure, established screening programs, and favorable reimbursement environments, while Europe follows closely with similar clinical adoption patterns. Asia-Pacific is emerging as a high-growth region as developing nations expand their oncology capabilities and invest in digital health infrastructure.

• •North America leads, supported by advanced healthcare infrastructure and LDCT screening reimbursement policies
• •Europe maintains a significant market share through national screening initiatives and diagnostic modernization
• •Asia-Pacific is accelerating adoption as emerging markets scale oncology and radiology digitalization efforts

What are the recent trends and outlook?

Ongoing advances in deep learning and computer vision are steadily improving the sensitivity and specificity of automated nodule detection, positioning AI as a standard component of future screening workflows. Regulatory agencies are increasingly issuing clearances for autonomous and semi-autonomous AI tools, which is expected to accelerate clinical adoption and reimbursement coverage. Over the longer term, the market is likely to benefit from integration with precision medicine initiatives, personalized risk modeling, and expanded screening eligibility criteria that incorporate genetic and lifestyle risk factors.

• •AI-assisted detection tools are gaining regulatory approvals and becoming embedded in standard radiology workflows
• •Cloud-native platforms are enabling multi-site coordination and longitudinal patient tracking across screening programs
• •Growing emphasis on personalized risk models and biomarker integration is expected to expand software functionality beyond imaging alone